▲ Peaking
Business
Q32’s stock jumps 60% on latest phase 2 alopecia data for potential rival to JAK inhibitors
Q32 Bio's stock surged 60% following positive Phase 2 data for Bempikibart, a potential rival to JAK inhibitors in treating alopecia areata.